Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Abbott VP John Leonard said the partnership with Genentech "will allow Abbott to build a world-class oncology franchise," while Genentech CMO Hal Barron said…
Brian Lawler argued the deal was not an Avastin hedge: "These deals don't signal a lack of confidence in its top compounds — in fact, they're good news for the…
Commentary on "From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia" notes navitoclax "mimicking a…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Global co-development of ABT-263 (Bcl-2 antagonist, navitoclax) and ABT-869. Financial terms undisclosed. Source: Fierce Biotech, PharmaTimes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Genentech Inc. (Roche Group) (this deal) | 2007 | — | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2007 deals · Abbott Laboratories deals